[EN] ISOQUINOLINES AS UROKINASE INHIBITORS<br/>[FR] ISOQUINOLINES EN TANT QU'INHIBITEURS DE L'UROKINASE
申请人:PFIZER LIMITED
公开号:WO1999020608A1
公开(公告)日:1999-04-29
(EN) Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is H and the other is N=C(NH2)2 or NHC(=NH)NH2, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.(FR) L'invention concerne des composés de formule (I) et leurs sels pharmaceutiquement acceptables, dans laquelle l'un des R1 et R2 représente H et l'autre représente N=C(NH2)2 ou NHC(=NH)NH2 et les autres substituants sont tels que définis. Les composés sont des inhibiteurs d'urokinase (uPA).
Compounds of formula (I):
and pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is H and the other is N═C(NH2)2 or NHC(═NH)NH2, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.
Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-Isoquinolinylguanidines
作者:Christopher G. Barber、Roger P. Dickinson、Paul V. Fish
DOI:10.1016/j.bmcl.2004.03.094
日期:2004.6
A series of 1-isoquinolinylguanidines are shown to be potent inhibitors of uPA with selectivity over tPA and plasmin. Potency is enhanced by the presence of a 4-halo and a 7-aryl substituent, particularly when substituted by a 3-carboxylic acid group. Compound 13j (UK-356,202) combines excellent potency and selectivity, and has been selected as a candidate for clinical evaluation. (C) 2004 Elsevier Ltd. All rights reserved.
PYRROLO-PYRIDINE DERIVATIVES
申请人:MERCK SHARP & DOHME LTD.
公开号:EP0687267A1
公开(公告)日:1995-12-20
PYRROLO-PYRIDINE DERIVATIVES AS LIGANDS OF DOPAMINE RECEPTOR